Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer


Introducing the RADAR studies

Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer. He covers when to use these tools by examining the published data, specifically the RADAR 1 and 3 studies. The RADAR (radiographic assessments for detection of advanced recurrence) group, are a team of experts, including Dr Koo, who have published articles pertinent to prostate cancer imaging. The initial paper of RADAR 1 reviewed imaging guidelines with associated clinical validation studies for metastatic prostate cancer. It provided recommendations for clinical practice to improve early detection of metastatic disease. RADAR III focuses on updates regarding next generation imaging for improved guidance.

Important findings for imaging metastatic prostate cancer

In this video and associated slides, Dr Koo details the RADAR 1 and 3 recommendations, comparing conventional imaging to advanced PET imaging for detection of metastatic disease in prostate cancer. Prostate cancer PET detection rates as a function of PSA in patients with biochemical recurrence are addressed. The suitability of radiotracers for next generation imaging is discussed, and how to approach different patient groups. Lastly, what test to use based on availability, accounting for location and coverage by MEDICARE. View the video and slides provided as part of our educational resources and practical guidance for medical oncologists and urologists.

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups. Dr Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Dr Phillip Koo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Blue Earth, Janssen, Lantheus, Merck and Novartis. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

GI-oncology-GI-CONNECT-10-years-thumbnail-GI2403 Video
Oncology 
Celebrating the 10th anniversary of GI CONNECT

10 years of independent medical education in GI oncology

Experts
Assoc. Prof. Gerald Prager, Assoc. Prof. Joleen Hubbard, Dr Thomas Winder, Prof. Andrea Sartore-Bianchi, Dr Dominik Modest
  • clock 2 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer